In the blockade of BTLA, an increase in the proliferation and expansion of NY-ESO-1-specific CD8+ T-cells was observed, and an increased efficiency of the use of antibodies targeting BTLA in combination with anti-PD-1 and anti-Tim-3 in melanoma was shown [214]. The gene discussed is HAVCR2; the disease is melanoma.